Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · July 25, 2018

CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection vs Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary AML

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
J. Clin. Oncol 2018 Jul 19;[EPub Ahead of Print], JE Lancet, GL Uy, JE Cortes, LF Newell, TL Lin, EK Ritchie, RK Stuart, SA Strickland, D Hogge, SR Solomon, RM Stone, DL Bixby, JE Kolitz, GJ Schiller, MJ Wieduwilt, DH Ryan, A Hoering, K Banerjee, M Chiarella, AC Louie, BC Medeiros

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading